Global genetic testing market is expected to reach USD 62,607,580.19 thousand by 2031 from USD 18,810,536.39 thousand in 2023, growing at a CAGR of 16.5% during the forecast period of 2024 to 2031.
Market Segmentation
Global Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Overview of Global Genetic Testing Market Dynamics
- Driver
- Growing prevalence of genetic disorders
- Restrain
- High cost of genetic testing
- Opportunity
- Strategic initiatives by the key market player
Market Players
Some of the key market players for global genetic testing market are:
- Thermo Fisher Scientific Inc.
- Invitae Corporation
- Bio-Rad Laboratories, Inc.
- PerkinElmer Inc.
- Illumina, Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- Fulgent Genetics
- Myriad Genetics, Inc.
- Abbott
- Eurofins Scientific
- Sorenson Genomics
- BIO-HELIX
- Biocartis
- Cepheid (A subsidiary of Danaher)
- PacBio
- ELITechGroup
- Genes2Me
- Eugene Labs
- Otogenetics
- Mapmygenome
- MedGenome
- BioReference
- Natera, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 68
- 1.1 OBJECTIVES OF THE STUDY 68
- 1.2 MARKET DEFINITION 68
- 1.3 OVERVIEW OF THE GLOBAL GENETIC TESTING MARKET 68
- 1.4 LIMITATIONS 70
- 1.5 MARKETS COVERED 70
2 MARKET SEGMENTATION 73
- 2.1 MARKETS COVERED 73
- 2.2 GEOGRAPHICAL SCOPE 74
- 2.3 YEARS CONSIDERED FOR THE STUDY 75
- 2.4 CURRENCY AND PRICING 75
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 76
- 2.6 TYPE LIFELINE CURVE 80
- 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81
- 2.8 DBMR MARKET POSITION GRID 82
- 2.9 MARKET APPLICATION COVERAGE GRID 83
- 2.10 VENDOR SHARE ANALYSIS 84
- 2.11 SECONDARY SOURCES 85
- 2.12 ASSUMPTIONS 85
3 EXECUTIVE SUMMARY 86
4 PREMIUM INSIGHTS 88
- 4.1 PESTAL ANALYSIS 91
- 4.2 PORTERS 5 FORCES 92
- 4.3 EPIDEMIOLOGY 93
5 GLOBAL GENETIC TESTING MARKET: REGULATIONS 94
6 MARKET OVERVIEW 96
- 6.1 DRIVERS 98
- 6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 98
- 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 98
- 6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 99
- 6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 99
- 6.2 RESTRAINTS 100
- 6.2.1 HIGH COST OF GENETIC TESTING 100
- 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 101
- 6.3 OPPORTUNITIES 101
- 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 101
- 6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 102
- 6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 102
- 6.4 CHALLENGES 103
- 6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 103
- 6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 104
7 GLOBAL GENETIC TESTING MARKET, BY TYPE 105
- 7.1 OVERVIEW 106
- 7.2 DIAGNOSTIC TESTING 110
- 7.3 PRENATAL TESTING 110
- 7.3.1 NON-INVASIVE SCREENING 111
- 7.3.1.1 WHOLE GENOME SEQUENCING 112
- 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 112
- 7.3.1.3 OTHERS 112
- 7.3.2 BY CONDITION 113
- 7.3.2.1 TRISOMY 21 113
- 7.3.2.2 KLINEFELTER SYNDROME 113
- 7.3.2.3 JACOBS SYNDROME 113
- 7.3.2.4 CYSTIC FIBROSIS 113
- 7.3.2.5 TURNER SYNDROME 114
- 7.3.2.6 TRISOMY 18 114
- 7.3.2.7 HEMOPHILIA 114
- 7.3.2.8 TRISOMY 13 114
- 7.3.2.9 MICRODELETION SYNDROME 114
- 7.3.2.10 FETAL GENDER 114
- 7.3.2.11 OTHERS 114
- 7.3.3 BY SCREENING TYPE 115
- 7.3.3.1 CARRIER SEQUENCING 115
- 7.3.3.2 SEQUENTIAL SEQUENCING 115
- 7.3.4 MATERNAL SERUM QUAD SCREENING 115
- 7.4 NEW-BORN SCREENING 116
- 7.4.1 SICKLE CELL DISEASE 116
- 7.4.2 CONGENITAL HYPOTHYROIDISM 117
- 7.4.3 PHENYLKETONURINA (PKU) 117
- 7.4.4 GALACTOSEMIA 117
- 7.4.5 MAPLE SYRUP URINE DISEASE 117
- 7.4.6 OTHERS 117
- 7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 117
- 7.6 CARRIER TESTING 118
- 7.6.1 MOLECULAR SCREENING TEST 118
- 7.6.2 BIOCHEMICAL SCREENING TEST 119
- 7.6.2.1 EXPANDED CARRIER SCREENING 119
- 7.6.2.2 PREDESIGNED PANEL TESTING 120
- 7.6.2.3 CUSTOM-MADE PANEL TESTING 120
- 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 120
- 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 120
- 7.6.2.4.2 PULMONARY CONDITIONS 121
- 7.6.2.4.3 NEUROLOGICAL CONDITIONS 121
- 7.6.2.4.4 OTHER CONDITIONS 121
- 7.7 OTHER TYPES 121
8 GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY 122
- 8.1 OVERVIEW 123
- 8.2 POLYMERASE CHAIN REACTION 126
- 8.2.1 REAL-TIME PCR (QPCR) 127
- 8.2.2 DIGITAL PCR (DPCR) 127
- 8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 127
- 8.2.4 HOT-START PCR 127
- 8.2.5 MULTIPLEX PCR 127
- 8.2.6 OTHER PCR 127
- 8.3 DNA SEQUENCING (NGS-BASED TESTING) 128
- 8.3.1 NEXT GENERATION SEQUENCING (NGS) 128
- 8.3.2 SANGER SEQUENCING (SINGLE GENE) 128
- 8.3.3 OTHER 129
- 8.4 WHOLE GENOME SEQUENCING 129
- 8.5 MICROARRAYS 129
- 8.5.1 DNA MICROARRAYS 130
- 8.5.2 PROTEIN MICROARRAYS 130
- 8.5.3 OTHER MICROARRAYS 130
- 8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 130
- 8.7 OTHERS 131
9 GLOBAL GENETIC TESTING MARKET, BY DISEASES 132
- 9.1 OVERVIEW 133
- 9.2 CANCER 136
- 9.2.1 BREAST 137
- 9.2.2 COLON 137
- 9.2.3 LUNG 137
- 9.2.4 PROSTATE 137
- 9.2.5 OTHERS 137
- 9.3 SICKLE CELL ANEMIA 138
- 9.4 THALASSEMIA 138
- 9.5 RARE GENETIC DISORDER 139
- 9.5.1 TRISOMY 21 139
- 9.5.2 MONOSOMY X 139
- 9.5.3 TRISOMY 13 140
- 9.5.4 MICRODELETION SYNDROME 140
- 9.5.5 TRISOMY 18 140
- 9.5.6 OTHERS 140
- 9.6 FRAGILE X SYNDROME 140
- 9.7 DUCHENNE MUSCULAR DYSTROPHY 141
- 9.8 HUNTINGTON'S DISEASE 141
- 9.9 CYSTIC FIBROSIS 142
- 9.10 OTHERS 142
10 GLOBAL GENETIC TESTING MARKET, BY END USER 143
- 10.1 OVERVIEW 144
- 10.2 HOSPITALS 147
- 10.3 CLINICS 148
- 10.4 DIAGNOSTIC CENTERS 148
- 10.5 PRIVATE CLINICS 149
- 10.6 LABORATORY SERVICE PROVIDERS 149
- 10.7 PRIVATE LABORATORIES 150
11 GLOBAL GENETIC TESTING MARKET, BY REGION 151
- 11.1 OVERVIEW 152
- 11.2 NORTH AMERICA 155
- 11.2.1 U.S. 165
- 11.2.2 CANADA 176
- 11.2.3 MEXICO 187
- 11.3 EUROPE 198
- 11.3.1 GERMANY 207
- 11.3.2 FRANCE 218
- 11.3.3 U.K. 229
- 11.3.4 RUSSIA 240
- 11.3.5 ITALY 251
- 11.3.6 SPAIN 261
- 11.3.7 TURKEY 272
- 11.3.8 NETHERLANDS 283
- 11.3.9 SWITZERLAND 294
- 11.3.10 BELGIUM 305
- 11.3.11 REST OF EUROPE 316
- 11.4 ASIA-PACIFIC 317
- 11.4.1 CHINA 326
- 11.4.2 JAPAN 337
- 11.4.3 INDIA 348
- 11.4.4 SOUTH KOREA 359
- 11.4.5 AUSTRALIA 370
- 11.4.6 SINAGPORE 381
- 11.4.7 THAILAND 392
- 11.4.8 INDONESIA 403
- 11.4.9 PHILIPPINES 414
- 11.4.10 MALAYSIA 425
- 11.4.11 VIETNAM 436
- 11.4.12 REST OF ASIA-PACIFIC 447
- 11.5 SOUTH AMERICA 448
- 11.5.1 BRAZIL 456
- 11.5.2 ARGENTINA 466
- 11.5.3 REST OF SOUTH AMERICA 477
- 11.6 MIDDLE EAST AND AFRICA 478
- 11.6.1 SOUTH AFRICA 488
- 11.6.2 SAUDI ARABIA 499
- 11.6.3 U.A.E. 510
- 11.6.4 ISRAEL 521
- 11.6.5 EGYPT 532
- 11.6.6 REST OF MIDDLE EAST AND AFRICA 543
12 GLOBAL GENETIC TESTING MARKET, COMPANY LANDSCAPE 544
- 12.1 COMPANY SHARE ANALYSIS: GLOBAL 544
13 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 545
- 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 545
14 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE 546
- 14.1 COMPANY SHARE ANALYSIS: EUROPE 546
15 ASIA-PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 547
- 15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 547
16 SWOT ANALYSIS 548
17 COMPANY PROFILES 549
- 17.1 ILLUMINA, INC. 549
- 17.1.1 COMPANY SNAPSHOT 549
- 17.1.2 REVENUE ANALYSIS 549
- 17.1.3 COMPANY SHARE ANALYSIS 550
- 17.1.4 PRODUCT PORTFOLIO 550
- 17.1.5 RECENT DEVELOPMENT 551
- 17.2 CEPHEID 552
- 17.2.1 COMPANY SNAPSHOT 552
- 17.2.2 REVENUE ANALYSIS 552
- 17.2.3 COMPANY SHARE ANALYSIS 553
- 17.2.4 PRODUCT PORTFOLIO 553
- 17.2.5 RECENT DEVELOPMENT 553
- 17.3 FULGENT GENETICS 554
- 17.3.1 COMPANY SNAPSHOT 554
- 17.3.2 REVENUE ANALYSIS 554
- 17.3.3 COMPANY SHARE ANALYSIS 555
- 17.3.4 PRODUCT PORTFOLIO 555
- 17.3.5 RECENT DEVELOPMENT 556
- 17.4 PERKINELMER INC. 557
- 17.4.1 COMPANY SNAPSHOT 557
- 17.4.2 REVENUE ANALYSIS 557
- 17.4.3 COMPANY SHARE ANALYSIS 558
- 17.4.4 PRODUCT PORTFOLIO 558
- 17.4.5 RECENT DEVELOPMENT 558
- 17.5 THERMO FISHER SCIENTIFIC INC. 559
- 17.5.1 COMPANY SNAPSHOT 559
- 17.5.2 REVENUE ANALYSIS 559
- 17.5.3 COMPANY SHARE ANALYSIS 560
- 17.5.4 PRODUCT PORTFOLIO 560
- 17.5.5 RECENT DEVELOPMENT 561
- 17.5.5.1 COLLABORATION 561
- 17.6 BIOREFERENCE 562
- 17.6.1 COMPANY SNAPSHOT 562
- 17.6.2 REVENUE ANALYSIS 562
- 17.6.3 PRODUCT PORTFOLIO 563
- 17.6.4 RECENT DEVELOPMENT 563
- 17.7 ELITECHGROUP 564
- 17.7.1 COMPANY SNAPSHOT 564
- 17.7.2 PRODUCT PORTFOLIO 564
- 17.7.3 RECENT DEVELOPMENTS 565
- 17.8 EUROFINS SCIENTIFIC 566
- 17.8.1 COMPANY SNAPSHOT 566
- 17.8.2 REVENUE ANALYSIS 566
- 17.8.3 PRODUCT PORTFOLIO 567
- 17.8.4 RECENT DEVELOPMENT 567
- 17.9 INVITAE CORPORATION 568
- 17.9.1 COMPANY SNAPSHOT 568
- 17.9.2 REVENUE ANALYSIS 568
- 17.9.3 PRODUCT PORTFOLIO 569
- 17.9.4 RECENT DEVELOPMENTS 569
- 17.10 MYRIAD GENETICS 570
- 17.10.1 COMPANY SNAPSHOT 570
- 17.10.2 REVENUE ANALYSIS 570
- 17.10.3 PRODUCT PORTFOLIO 571
- 17.10.4 RECENT DEVELOPMENT 571
- 17.11 ABBOTT 572
- 17.11.1 COMPANY SNAPSHOT 572
- 17.11.2 REVENUE ANALYSIS 572
- 17.11.3 PRODUCT PORTFOLIO 573
- 17.11.4 RECENT DEVELOPMENT 573
- 17.12 BIOCARTIS 574
- 17.12.1 COMPANY SNAPSHOT 574
- 17.12.2 REVENUE ANALYSIS 574
- 17.12.3 PRODUCT PORTFOLIO 575
- 17.12.4 RECENT DEVELOPMENTS 575
- 17.12.4.1 PARTNERSHIP 575
- 17.13 BIO-HELIX 576
- 17.13.1 COMPANY SNAPSHOT 576
- 17.13.2 PRODUCT PORTFOLIO 576
- 17.13.3 RECENT DEVELOPMENT 576
- 17.14 BIO-RAD LABORATORIES, INC. 577
- 17.14.1 COMPANY SNAPSHOT 577
- 17.14.2 REVENUE ANALYSIS 577
- 17.14.3 PRODUCT PORTFOLIO 578
- 17.14.4 RECENT DEVELOPMENTS 578
- 17.15 EUGENE LABS 579
- 17.15.1 COMPANY SNAPSHOT 579
- 17.15.2 PRODUCT PORTFOLIO 579
- 17.15.3 RECENT DEVELOPMENT 579
- 17.16 F. HOFFMANN-LA ROCHE LTD 580
- 17.16.1 COMPANY SNAPSHOT 580
- 17.16.2 REVENUE ANALYSIS (PARENT COMPANY) 580
- 17.16.3 PRODUCT PORTFOLIO 581
- 17.16.4 RECENT DEVELOPMENT 581
- 17.17 GENES2ME 582
- 17.17.1 COMPANY SNAPSHOT 582
- 17.17.2 PRODUCT PORTFOLIO 582
- 17.17.3 RECENT DEVELOPMENT 582
- 17.18 MAPMYGENOME 583
- 17.18.1 COMPANY SNAPSHOT 583
- 17.18.2 PRODUCT PORTFOLIO 583
- 17.18.3 RECENT DEVELOPMENT 584
- 17.19 MEDGENOME 585
- 17.19.1 COMPANY SNAPSHOT 585
- 17.19.2 PRODUCT PORTFOLIO 585
- 17.19.3 RECENT DEVELOPMENT 586
- 17.20 NATERA, INC. 587
- 17.20.1 COMPANY SNAPSHOT 587
- 17.20.2 REVENUE ANALYSIS 587
- 17.20.3 PRODUCT PORTFOLIO 588
- 17.20.4 RECENT DEVELOPMENT 589
- 17.21 OTOGENETICS 590
- 17.21.1 COMPANY SNAPSHOT 590
- 17.21.2 PRODUCT PORTFOLIO 591
- 17.21.3 RECENT DEVELOPMENT 591
- 17.22 PACBIO 592
- 17.22.1 COMPANY SNAPSHOT 592
- 17.22.2 REVENUE ANALYSIS 592
- 17.22.3 PRODUCT PORTFOLIO 593
- 17.22.4 RECENT DEVELOPMENT 593
- 17.23 QIAGEN 594
- 17.23.1 COMPANY SNAPSHOT 594
- 17.23.2 REVENUE ANALYSIS 594
- 17.23.3 PRODUCT PORTFOLIO 595
- 17.23.4 RECENT DEVELOPMENT 595
- 17.24 SORENSON GENOMICS 596
- 17.24.1 COMPANY SNAPSHOT 596
- 17.24.2 PRODUCT PORTFOLIO 596
- 17.24.3 RECENT DEVELOPMENT 596
18 QUESTIONNAIRE 597
19 RELATED REPORTS 600